New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for NefeconĀ® for the Treatment of Primary IgA Nephropathy


STOCKHOLM, Oct. 27, 2023 /PRNewswire/ — Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that its commercial partner Everest Medicines (HKEX 1952.HK) (“Everest”) received approval from the Pharmaceutical Administration Bureau of the Macau…

Leave a Reply